Bruker AXS Completes Acquisition of SOCABIM; Expands its Core X-ray Technology BaseSOCABIM's next generation DIFFRACPlus Eva XRD
18 January 2006 - 8:15AM
Business Wire
Bruker AXS GmbH announced today that it has completed the
acquisition of privately-held SOCABIM SAS, a company focused on
advanced X-ray analysis software for materials research. This
acquisition was originally announced on August 16, 2005, and was
expected to close early in 2006. The acquisition of SOCABIM
significantly expands Bruker AXS' core technology base in two of
its strategic product and applications areas. It is expected that
the addition of the SOCABIM technology and R&D team will
further improve the "time-to-market," the analytical power and the
user-friendliness of Bruker AXS' X-ray systems for advanced
research and process analysis in the nanomaterials, thin film,
composite materials, semiconductor and basic materials industries.
ABOUT BRUKER BIOSCIENCES (NASDAQ: BRKR) Bruker BioSciences
Corporation, headquartered in Billerica, Massachusetts, is the
publicly traded parent company of Bruker Daltonics Inc. and Bruker
AXS Inc. Bruker AXS is a leading developer and provider of life
science and advanced materials research tools based on x-ray
technology. Bruker Daltonics is a leading developer and provider of
innovative life science tools based on mass spectrometry. For more
information, please visit www.bruker-biosciences.com. CAUTIONARY
STATEMENT Any statements contained in this press release that do
not describe historical facts may constitute forward-looking
statements as that term is defined in the Private Securities
Litigation Reform Act of 1995. Any forward-looking statements
contained herein are based on current expectations, but are subject
to a number of risks and uncertainties. The factors that could
cause actual future results to differ materially from current
expectations include, but are not limited to, risks and
uncertainties relating to the Company's reorganization strategies,
integration risks, failure of conditions, technological approaches,
product development, market acceptance, cost and pricing of the
Company's products, exposure to currency fluctuations, changes in
governmental regulations, capital spending and government funding
policies, FDA and other regulatory approvals to the extent
applicable, competition, the intellectual property of others,
patent protection and litigation. These and other factors are
identified and described in more detail in our filings with the
SEC, including, without limitation, our respective annual reports
on Form 10-K for the year ended December 31, 2004, our most recent
quarterly reports on Form 10-Q, and our current reports on Form
8-K. We disclaim any intent or obligation to update these
forward-looking statements.
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Jul 2023 to Jul 2024